Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France

Hernández-Hernández, Francisca; Fréalle, Émilie; Caneiro, Patrick; Salleron, Julia; Durand-Joly, Isabelle; Accoceberry, Isabelle; Bouchara, Jean‐Philippe; Wallaert, B.; Dei‐Cas, Eduardo; Delhaès, Laurence

doi:10.1128/jcm.01974-12

Cited by 23 publications

(22 citation statements)

References 32 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identification of P jirovecii in CF patients is described throughout the world, with regional differences appreciated. French studies describe a prevalence of P jirovecii of 2.5–12.5%, while a cohort of Brazilian CF patients had a prevalence of 38.2% …”

Section: Epidemiologymentioning

confidence: 99%

The myriad challenges of respiratory fungal infection in cystic fibrosis

Tracy

Moss

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

Fungal infection in cystic fibrosis (CF) is a recognized challenge, with many areas requiring further investigation. Consensus definitions exist for allergic bronchopulmonary aspergillus in CF, but the full scope of clinically relevant non-allergic fungal disease in CF-asymptomatic colonization, transient or chronic infection localized to endobronchial mucus plugs or airway tissue, and invasive disease-is yet to be clearly defined. Recent advances in mycological culture and non-culture identification have expanded the list of both potential pathogens and community commensals in the lower respiratory tract. Here we aim to outline the current understanding of fungal presence in the CF respiratory tract, risk factors for acquiring fungi, host-pathogen interactions that influence the role of fungi from bystander to pathogen, advances in the diagnostic approaches to isolating and identifying fungi in CF respiratory samples, challenges of classifying clinical phenotypes of CF patients with fungi, and current treatment approaches. Development and validation of biomarkers characteristic of different fungal clinical phenotypes, and controlled trials of antifungal agents in well-characterized target populations, remain central challenges to surmount and goals to be achieved.

show abstract

Section: Epidemiologymentioning

confidence: 99%

The myriad challenges of respiratory fungal infection in cystic fibrosis

Tracy

Moss

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…These patients were more likely to have mild disease and be free of P aeruginosa. 99 A fungal agent that has recently emerged in patients with CF is Trichosporon. With the increasing use of antifungal agents to treat disease associated with Aspergillus and Scedosporium, Trichosporon, which is resistant to the antifungals amphotericin and the echinocandins, may find a niche in the CF airway.…”

Section: Infections In Patients With Cystic Fibrosismentioning

confidence: 99%

Infections in Patients with Cystic Fibrosis

Gilligan

2014

Clinics in Laboratory Medicine

View full text Add to dashboard Cite

Survival has improved in patients with cystic fibrosis (CF), in part because of aggressive antimicrobial management. Two multidrug-resistant environmental bacteria, the Burkholderia cepacia group and nontuberculous mycobacteria, have emerged. Improving genomic and proteomic technologies are allowing better identification of bacteria and fungi found in the CF lung and detection of viral agents that may be associated with pulmonary exacerbations. Anaerobic bacteria and Streptococcus angionsus group organisms may play a role in chronic CF lung infections. The diversity of organisms declines perhaps as a result of aggressive antimicrobial therapy, and an apex predator, Pseudomonas aeruginosa, may emerge in many patients with CF.

show abstract

“…Pneumocystis pneumonia is reported mainly in immunocompromised children and has been rarely reported in children with CF . Our patient was found to have P. jirovecii .…”

Section: Discussionmentioning

confidence: 52%